相关临床试验
372
47 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
33
8.9%
已完成
219
58.9%
尚未招募
14
3.8%
招募中
69
18.6%
暂停
4
1.1%
终止
12
3.2%
Unknown
3
0.8%
撤回
18
4.8%
暂无批准数据
- The FDA has granted fast track designation to NG-350A, an oncolytic immunotherapy developed by Akamis Bio, for treating mismatch repair-proficient locally advanced rectal cancer. - NG-350A is designed to drive intratumoral expression of a CD40 agonist monoclonal antibody, activating antigen-presenting cells and recruiting T cells to deliver potent anti-tumor immune responses. - The therapy is being evaluated in the phase 1b FORTRESS trial combining NG-350A with chemoradiotherapy in approximately 30 patients with locally advanced rectal cancer. - Patients with mismatch repair-proficient tumors represent approximately 90% of locally advanced rectal cancer cases, highlighting a significant unmet medical need for new therapeutic approaches.
- Nanopharmaceutics has completed enrollment of 94 patients in a National Cancer Institute-sponsored Phase II randomized trial testing Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for metastatic neuroendocrine tumors. - The study passed pre-planned interim safety review and futility assessment, with primary endpoint data awaiting maturity to evaluate overall response rates between the combination and standard therapy arms. - Phase I study results combining Triapine with lutetium Lu 177 dotatate will be presented at the 2025 ESMO Congress, marking continued advancement of this ribonucleotide reductase inhibitor approach. - The trials are conducted under a Cooperative Research and Development Agreement between the NCI and Nanopharmaceutics through the Experimental Therapeutics Clinical Trials Network.
- TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT). - The collaboration will initially focus on preclinical evaluation of proprietary boron-10 drugs in cellular and animal models, utilizing Ohio State's specialized neutron source optimized for BNCT research. - This partnership aims to position the United States as a leader in BNCT innovation, following promising clinical evidence from Japan, Taiwan, and Europe showing durable responses in patients with otherwise untreatable cancers.
- The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024. - University of Kentucky's Markey Cancer Center is transforming clinical trial participation by addressing misconceptions and adapting terminology to build trust, particularly among marginalized communities. - Community-based initiatives, including Cowell Family Cancer Center's bispecific antibody program and wellness initiatives at Fox Chase Cancer Center, are expanding access to advanced cancer treatments and support services.
- A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma. - HOSU-53, developed at Ohio State, targets dihydroorotate dehydrogenase (DHODH), a key enzyme in cancer cell metabolism, aiming to disrupt DNA and RNA synthesis. - Preclinical studies suggest HOSU-53 can selectively starve cancer cells by depriving them of pyrimidines, potentially enhancing the efficacy of other cancer therapies. - The trial, led by the OSUCCC – James, represents the first human testing of this best-in-class DHODH inhibitor, with Jabez Biosciences as the industrial development partner.
- Nanopharmaceutics has completed patient enrollment in a 94-patient Phase 2 randomized controlled trial evaluating Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors. - The NCI-sponsored study passed pre-planned interim safety review and futility assessment, with the trial now awaiting primary endpoint maturity to evaluate overall response rate and progression-free survival. - Triapine, a ribonucleotide reductase inhibitor, is being tested to determine if adding it to the standard radioconjugate therapy improves tumor shrinkage or slows growth in patients with metastatic neuroendocrine tumors.
